American Century Companies’s Ovid Therapeutics OVID Stock Holding History

American Century Companies’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,071	Closed	-$19K	–	2608
2022 Q3	$19K	Sell	10,071 -27,230	-73%	-$57K	﹤0.01%	2425
2022 Q2	$80K	Sell	37,301 -19,574	-34%	-$47.3K	﹤0.01%	2250
2022 Q1	$179K	Buy	56,875 +9,994	+21%	+$31.4K	﹤0.01%	2196
2021 Q4	$150K	Buy	46,881 +9,030	+24%	+$30.9K	﹤0.01%	2218
2021 Q3	$127K	Buy	+37,851	New	+$138K	﹤0.01%	2223

Other funds holding OVID

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

American Century Companies's OVID Position: Q4 2022 in Review

American Century Companies sold out of Ovid Therapeutics (OVID) in Q4 2022, closing a stake of 10,071 shares — an estimated $19K sold.

American Century Companies first reported a position in OVID in Q3 2021 and held it in 5 quarters. The position peaked at $179K in Q1 2022. 60 funds tracked by Wall St. Rank hold OVID as of Q4 2022.

American Century Companies reported no remaining Ovid Therapeutics position as of Q4 2022 after selling out during the quarter.
American Century Companies sold 10,071 Ovid Therapeutics shares in Q4 2022, an estimated $19K.
American Century Companies first reported a position in Ovid Therapeutics in Q3 2021 and held it in 5 quarters.
American Century Companies's Ovid Therapeutics position peaked at $179K in Q1 2022.
60 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q4 2022.

Based on American Century Companies's 13F filing for Q4 2022, filed 13 Feb 2023.